by Marc Puich | November 15, 2019
At Biomanufacturing World Summit this week, leaders at the forefront of producing cell and gene therapies gathered to talk about what’s really required to produce deeply individualized therapeutics at scale. Here are a few of the highlights:
Chain of Identity and Chain of Custody in personalized therapies -- core differences from traditional pharma
by Heidi Hagen | October 30, 2019
In pharmaceutical manufacturing, Chain of Identity and Chain of Custody may not be new -- but in advanced therapy manufacturing, they take on a whole new significance. Why? Because in personalized therapies, a person is a key part of the process.
by Vineti | October 23, 2019
Mike Pellini, M.D., is a member of Vineti’s Board of Directors, a Managing Partner at Section 32, and the former CEO and Chairman of cancer genomics trailblazer Foundation Medicine. He is a leading voice on how the life sciences will continue to…
by Heidi Hagen | October 17, 2019
Why is the distinction between the supply chain and value chain important in cell therapies, gene therapies, and personalized cancer vaccines? As it turns out, it all comes back to the patient.
by Heidi Hagen | August 27, 2019
Next month, my colleagues at Vineti and I will be speaking, writing, and presenting on a topic of critical importance to cell and gene therapy -- data management. Why now? Because in advanced therapeutics, data management is patient management. To…